Keywords: Sanofi-Aventis, Ascenta Thera, Tumor cell apoptosis, License,
Sanofi-Aventis in cancer licensing deal with Ascenta, worth up to $398 million to the US firm
Article | 04 June 2010
Announcing a third research collaboration in little over a week, French drug major Sanofi-Aventis has signed an exclusive global collaboration ...
Enjoying this article? To continue reading you need to login or subscribe.
Subscribe now
for unlimited access to all articles
Subscriptions are £60 per month, pay as you go.
Find out more details.
Already a subscriber? Click here to log in
- AstraZeneca's naloxegol meets endpoints; EMA validates Gilead's sofosbuvir MAA
- Is failure to adopt business process management putting the pharma industry at risk?
- Boehringer Ingelheim gets FDA warning letter on cGMP failures
- Sanofi and Regeneron's dupilumab shows 87% reduction in risk of asthma exacerbations
- Ignyta acquires Actagene Oncology and entry into cancer personalized medicine
